Identification and external validation of the sets of 4-, 6-, 8-, 12-, and 24-hour CGM motifs
Organizations: School of Data Science, University of Virginia, Charlottesville, VA 22904 · Center for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, VA 22903
Abstract
There is growing interest in using CGM for purposes other than those initially intended. Recent work of Lobo et al. identified : a set of motifs such that almost any daily CGM profile (the 24-hour CGM time series starting at midnight) can be classified - matched to a motif in . This work generalizes the prior work by identifying sets of motifs for 4-, 6-, 8-, 12-, and 24-hr CGM profiles where an -hr CGM profile does not have to be 24 hours in length, and does not have to start at midnight. The prior work methods are modified to identify the five new sets of motifs using data from the same 6 studies in the original work. The newly identified sets were subjected to rigorous external validation using a data set comprised of data from 21 studies (3,455 subjects, 289,592 days of CGM data). The external validation data set has both temporal and geographic transportability and addresses limitations of the data set used to define the five new sets of motifs. The results of the external validation indicate that the prior work generalizes well: the performance of each -hr set of motifs on the external validation set is almost identical to that obtained for . The generalization of the original work broadens the potential use cases of the framework to include short term predictions (e.g., impending hypoglycemia) and diagnostics which rely on detecting changes in CGM time series which are less than 24 hours in length.
Figures & tables
| No. of | Unclassified 4-hr | Cluster Size | Max. | |
|---|---|---|---|---|
| Motifs | CGM Profiles (%) | Mean (Stdev) | Cluster Size | |
| 0.50 | 1135 | 1121 (2.24) | 43.07 (37.49) | 275 |
| 0.75 | 661 | 1002 (2.00) | 74.13 (79.95) | 575 |
| 1.00 | 419 | 620 (1.24) | 117.85 (144.31) | 913 |
| 1.25 | 293 | 526 (1.05) | 168.85 (232.46) | 1360 |
| 1.50 | 208 | 273 (0.55) | 239.07 (362.97) | 2177 |
| Testing Data Set | % of Testing Data Set | |||
|---|---|---|---|---|
| Size | Unclassified | |||
| 4 | 1.25 | 293 | 3,363,347 | 1.05 |
| 6 | 1.25 | 371 | 1,639,797 | 1.18 |
| 8 | 1.5 | 310 | 1,059,918 | 1.01 |
| 12 | 1.5 | 344 | 748,123 | 1.01 |
| 24 | 1.25 | 494 | 312,845 | 1.35 |
| Testing Data Set | External Validation Data Set | ||||
|---|---|---|---|---|---|
| Subjects | Days of Data | Subjects | Days of Data | ||
| Sex | Female | 251 (51.2%) | 20,664 (52.8%) | 2,181 (63.1%) | 183,450 (63.3%) |
| Male | 239 (48.8%) | 18,498 (47.2%) | 1,220 (35.3%) | 105,954 (36.6%) | |
| Unknown | 0 (0.0%) | 0 (0.0%) | 54 (1.6%) | 188 (0.1%) | |
| Age, y | 0 (0.0%) | 0 (0.0%) | 561 (16.2%) | 48,464 (16.7%) | |
| Ext. Validation | % of Ext. Validation | |
|---|---|---|
| Set Size | Set Unclassified | |
| 4 | 19,649,740 | 1.61 |
| 6 | 9,488,956 | 1.66 |
| 8 | 6,085,093 | 1.42 |
| 12 | 4,238,607 | 1.23 |
| 24 | 1,727,837 | 1.47 |
Appendix figures & tables10 assets
Supplementary material from the paper’s appendix.
Appendix
| Name (Trial ID) | Time Frame | Geographic Locations | Description (Study Group) |
|---|---|---|---|
| Dclp1 (NCT02985866) | 10/2017–09/2018 | 7 U.S. academic diabetes centers | Randomized, unblinded clinical trial to assess the efficacy of inControl AP: a mobile CLC system [ 12 ] (International Diabetes Closed Loop Study Group) |
| Dclp3 (NCT03563313) | 06/2018–04/2019 | 7 U.S. academic diabetes centers | Randomized trial to assess the efficacy of CLC over sensor-augmented pump [ 13 ] (iDCL Trial Research Group) |
| Dia1 (NCT02282397) | 09/2014–11/2016 | 24 U.S. endocrinology practices (19 community-based, 5 academic centers) | Randomized clinical trial to determine the effectiveness of CGM in adults with T1D treated with insulin injections [ 14 ] (DIAMOND Study Group) |
| Dia2 (NCT02282397) | 09/2014–11/2016 | 25 N.A. endocrinology practices (22 U.S., 3 Canadian; 19 community-based, 6 academic centers) | Randomized clinical trial to determine the effectiveness of CGM in adults with T2D receiving multiple daily injections of insulin [ 15 ] (DIAMOND Study Group) |
| Dss1 (NCT03093636) | 04/2017–03/2019 | 3 U.S. academic diabetes centers | Randomized clinical trial to assess the safety and efficacy of a CGM-based decision support system that provides real-time dosing advice and retrospective therapy optimization [ 16 ] |
| Ntlt (NCT02679287) | 02/2016–04/2019 | 1 U.S. academic diabetes center | Randomized crossover trial to compare different configurations of a CLC system with activation of automated insulin delivery during the evening and overnight hours compared with continuous 24/7 CLC, and both treatment modalities compared with sensor-augmented insulin pump use [ 17 ] |
| No. of | Unclassified 6-hr | Cluster Size | Max. | |
|---|---|---|---|---|
| Motifs | CGM Profiles (%) | Mean (Stdev) | Cluster Size | |
| 0.50 | 1389 | 1175 (2.35) | 35.15 (26.55) | 208 |
| 0.75 | 838 | 1021 (2.04) | 58.45 (50.82) | 347 |
| 1.00 | 543 | 746 (1.49) | 90.71 (93.32) | 576 |
| 1.25 | 371 | 531 (1.06) | 133.34 (158.78) | 1029 |
| 1.50 | 271 | 380 (0.76) | 183.10 (246.95) | 1567 |
| No. of | Unclassified 8-hr | Cluster Size | Max. | |
|---|---|---|---|---|
| Motifs | CGM Profiles (%) | Mean (Stdev) | Cluster Size | |
| 0.50 | 1559 | 1382 (2.76) | 31.19 (22.82) | 138 |
| 0.75 | 953 | 1175 (2.35) | 51.23 (39.83) | 265 |
| 1.00 | 626 | 882 (1.76) | 78.46 (70.69) | 473 |
| 1.25 | 426 | 611 (1.22) | 115.94 (117.94) | 755 |
| 1.50 | 310 | 455 (0.91) | 159.82 (186.62) | 1228 |
| No. of | Unclassified 12-hr | Cluster Size | Max. | |
|---|---|---|---|---|
| Motifs | CGM Profiles (%) | Mean (Stdev) | Cluster Size | |
| 0.50 | 1722 | 1597 (3.19) | 28.11 (20.45) | 164 |
| 0.75 | 1081 | 1216 (2.43) | 45.13 (30.99) | 221 |
| 1.00 | 699 | 737 (1.47) | 70.48 (53.15) | 379 |
| 1.25 | 474 | 781 (1.56) | 103.84 (85.27) | 596 |
| 1.50 | 344 | 468 (0.94) | 143.99 (143.71) | 1088 |
| No. of | Unclassified 24-hr | Cluster Size | Max. | |
|---|---|---|---|---|
| Motifs | CGM Profiles (%) | Mean (Stdev) | Cluster Size | |
| 0.50 | 1740 | 727 (3.29) | 12.28 (9.58) | 68 |
| 0.75 | 1102 | 525 (2.38) | 19.57 (14.15) | 119 |
| 1.00 | 707 | 508 (2.30) | 30.53 (21.10) | 135 |
| 1.25 | 494 | 249 (1.13) | 44.22 (31.60) | 207 |
| 1.50 | 371 | 117 (0.53) | 59.24 (51.53) | 333 |
| Name (Trial ID) | Time Frame | Geographic Locations | Description (Study Group) |
|---|---|---|---|
| Aide1 (NCT04016662) | 09/2020–01/2024 | 2 U.S. diabetes centers, 2 U.S. academic medical centers | A randomized cross-over trial to evaluate the effect of different AID on hypoglycemia and quality of life in elderly adults with T1D [ 19 ] |
| City (NCT03263494) | 01/2018–11/2019 | 14 U.S. endocrinology practices | Randomized clinical trial determine the effect of CGM on glycemic control in adolescents and young adults with T1D [ 20 ] (CGM Intervention in Teens and Young Adults with T1D Study Group) |
| Ctr (NCT01271023) | 03/2011–08/2012 | 3 U.S. academic medical centers, 1 U.S. diabetes center, 2 European academic medical centers, 1 Middle Eastern medical center | A multi-national artificial pancreas study designed to minimize the time spent in hypo- and hyperglycaemic ranges using CGM and subcutaneous insulin infusion in individuals with T1D [ 21 , 22 ] (Control to Range Writing Group) |
| Ctr3 (NCT02137512) | 08/2014–11/2015 | 3 U.S. academic medical centers, 1 European academic medical centers | A multi-center trial of 24/7 automated insulin delivery to establish safety of 24/7 CLC during free-living conditions [ 23 ] (Control to Range Study Group) |
| Dclp5 (NCT03844789) | 06/2019–03/2020 | 4 U.S. pediatric diabetes centers | Randomized clinical trial of at-home CLC versus standard of care (PUMP) in youth aged 6–13 years of age [ 24 ] (iDCL Trial Research Group) |
| Flair (NCT03040414) | 06/2019–04/2020 | 1 non-U.S. academic medical center, 2 non-U.S. diabetes centers, 2 U.S. academic medical centers, 2 U.S. diabetes centers | A randomized crossover trial to compare the efficacy and safety of an AID system with a PID algorithm versus an AID system with a PID algorithm enhanced with a Fuzzy Logic algorithm [ 25 ] (Fuzzy Logic Automated Insulin Regulation Study Group) |